Phaseline

Companies › Chugai Pharmaceutical

Chugai Pharmaceutical: clinical trials, targets and expected readouts

6 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Hematology, Gastroenterology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DONQ52–Phase 2Celiac DiseaseJun 2027
RAY121
Classical complement pathway inhibitor
–Phase 1Antiphospholipid Syndrome (APS)Mar 2027
ROSE12–Phase 1Solid TumorOct 2027
ALPS12
CD20/CD3 bispecific antibody
–Phase 1Extensive Stage Small Cell Lung CancerSep 2028
AUBE00
Mechanism unclear
–Phase 1Solid TumorsDec 2029
AQUA07–Phase 1ALK Positive Non-small Cell Lung CancerAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06371417RAY121Phase 1Antiphospholipid Syndrome (APS)HematologyMar 2027
NCT07239336DONQ52Phase 2Celiac DiseaseGastroenterologyJun 2027
NCT05907980ROSE12Phase 1Solid TumorOncologyOct 2027
NCT07107490ALPS12Phase 1Extensive Stage Small Cell Lung CancerOncologySep 2028
NCT07030959AUBE00Phase 1Solid TumorsOncologyDec 2029
NCT07617337AQUA07Phase 1ALK Positive Non-small Cell Lung CancerOncologyAug 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.